MabVax Therapeutics Holdings, Inc. is a clinical stage biotechnology company focused on the development of antibody based products and vaccines to address unmet medical needs in the treatment of cancer. MabVax has discovered a pipeline of human monoclonal antibody products based on the protective immune responses generated by patients who have been immunized against targeted cancers with the Company s proprietary vaccines. MabVax also has the exclusive license to the therapeutic vaccines from Memorial Sloan Kettering Cancer Center. In December MabVax received authorization from the U.S. Food and Drug Administration, or FDA, to proceed with initiation of a Phase I clinical trial with HuMab B MVT as a therapeutic treatment for pancreatic cancer. Patient enrollment in the Phase I clinical trial was initiated in the first quarter of . In February MabVax announced the FDA had provided authorization to proceed with Zr HuMab B MVT , utilizing our fully human antibody product as a new generation PET scan cancer imaging agent. We expect patient enrollment for the new generation PET scan cancer imaging agent to begin in the second quarter of . MabVax also has two cancer vaccines targeting recurrent sarcoma and ovarian cancer in proof of concept Phase II multicenter clinical trials. Additional information is available at www.mabvax.com.
Quote | MabVax Therapeutics Holdings Inc. (OTCMKTS:MBVX)
Last: | $ |
---|---|
Change Percent: | -5.91% |
Open: | $0.12 |
Close: | $0.11055 |
High: | $0.139 |
Low: | $0.106 |
Volume: | 114,400 |
Last Trade Date Time: | 12/31/1969 07:00:00 pm |
News | MabVax Therapeutics Holdings Inc. (OTCMKTS:MBVX)
Message Board Posts | MabVax Therapeutics Holdings Inc. (OTCMKTS:MBVX)
Subject | By | Source | When |
---|---|---|---|
No posts yet. |